MS patients in Scotland must pay for treatment

Patients with relapsing remitting MS (RRMS) cannot be given natalizumab (Tysabri) on the NHS in Scotland despite good clinical outcomes because it is too expensive.

The Scottish Medicines Consortium (SMC) said that the economic case for providing the drug on the NHS has not been demonstrated.

It calculated that the cost per quality adjusted life year (QALY) for natalizumab is £32,000 com-pared with beta interferon and £31,000 compared with glatiramer acetate.

But the SMC acknowledged that clinical evidence showed that, compared with placebo, natalizumab significantly reduced relapse rate in patients with rapidly evolving severe RRMS. Sustained progression of disability over two years was also significantly less likely in patients given natalizumab.

Natalizumab is believed to reduce inflammation and demyelination in MS by inhibiting migration of leukocytes into the central nervous system. It is licensed as a single disease modifying therapy in highly active relapsing remitting MS (RRMS) if patients have rapidly developing disease or do not respond to beta interferon.

MS charities said the decision left doctors with no treatment al-ternatives for these patients.

Patients will only be able to receive natalizumab if they fund the drug themselves or if Scottish health boards take the unusual step of overruling the SMC advice.

Chief executive of the MS Trust Chris Jones said: ‘Clinicians will be prevented from prescribing an effective licensed treatment to people in need. We urge people with MS to continue fighting for Tysabri on an individual basis.’

Mark Hazelwood, director of the MS Society Scotland, said: ‘No other drug has shown this poten-tial to reduce disability and any short-term savings are likely to be outpaced by the devastating financial costs of living with severe, progressive disability.

‘Longer-term, we are concerned about the implications this might have on the forthcoming NICE decision this summer,’ he added.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

150,000 more people with learning disabilities prioritised for COVID-19 vaccine

150,000 more people with learning disabilities prioritised for COVID-19 vaccine

Around 150,000 more people will be prioritised for COVID-19 vaccination after the...

Dilemma: What should I do if a practice staff member refuses the COVID-19 vaccine?

Dilemma: What should I do if a practice staff member refuses the COVID-19 vaccine?

Dr Peter Mackenzie and Ceylan Simsek from Medical Protection offer some guidance...

GP sites could deliver 100m COVID-19 jabs in 2021 under government vaccine plan

GP sites could deliver 100m COVID-19 jabs in 2021 under government vaccine plan

GP-led sites could deliver more than 100m doses of COVID-19 vaccine this year under...

GP practices trialling HPV home testing could trigger national cervical screening overhaul

GP practices trialling HPV home testing could trigger national cervical screening overhaul

Female patients from 166 GP practices in London will be offered HPV home testing...

Updated COVID-19 enhanced service offers extra funding to vaccinate hard to reach groups

Updated COVID-19 enhanced service offers extra funding to vaccinate hard to reach groups

GP practices could be offered 'additional discretionary payments' to boost vaccine...